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Adverse drug events (ADEs) are more likely to affect geriatric patients due to physiological
changes occurring with aging. Even though this is an internationally recognized problem,
similar research data in Finland is still lacking. The aim of this study was to determine the
number of geriatric medication-related hospitalizations in the Finnish patient population
and to discover the potential means of recognizing patients particularly at risk of
ADEs. The study was conducted retrospectively from the 2014 emergency department
patient records in Oulu University Hospital. A total number of 290 admissions were
screened for ADEs, adverse drug reactions (ADRs) and drug-drug interactions (DDIs)
by a multi-disciplinary research team. Customized Naranjo scale was used as a control
method. All admissions were categorized into “probable,” “possible,” or “doubtful” by
both assessment methods. In total, 23.1% of admissions were categorized as “probably”
or “possibly” medication-related. Vertigo, falling, and fractures formed the largest group of
ADEs. The most common ADEs were related to medicines from N class of the ATC-code
system. Age, sex, residence, or specialty did not increase the risk for medication-related
admission significantly (min p = 0.077). Polypharmacy was, however, found to increase
the risk (OR 3.3; 95%CI, 1.5–6.9; p= 0.01). In conclusion, screening patients for specific
demographics or symptoms would not significantly improve the recognition of ADEs. In
addition, as ADE detection today is largely based on voluntary reporting systems and
retrospective manual tracking of errors, it is evident that more effective methods for ADE
detection are needed in the future.
Keywords: adverse drug events, adverse drug reactions, drug-drug interactions, elderly, polypharmacy,
hospitalization
INTRODUCTION
Medicating geriatric patients is a process that requires more thought and planning than medicating
younger adults. The reason for this lies partly in the physiological changes that occur with aging,
e.g., changes in the body mass distribution, renal function, metabolic capacity, and alterations
in blood protein levels (Mangoni and Jackson, 2003; Notenboom et al., 2014). Similar changes
often increase morbidity in the aged population by weakening homeostasis but also change
the pharmacodynamics and pharmacokinetics of many drugs. In addition, the inter-individual
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variation in these physiological changes increases with age.
Therefore, it can be a challenge to predict what effect even a
common medicine can have in a geriatric patient. On the other
hand, weakening cognition and other practical problems can
cause unwanted results in pharmacotherapy through unintended
mishaps (Mangoni and Jackson, 2003; Notenboom et al., 2014).
There is also an evident lack in the information on drug use in
the geriatric patient population.
Altered drug pharmacokinetics and pharmacodynamics,
frailty, multiple comorbidities, and simultaneous use of multiple
medicines (i.e., polypharmacy) result in an increased risk for
drug-drug interactions (DDIs), adverse drug reactions (ADRs),
and adverse drug events (ADEs) in the geriatric population
(Mangoni and Jackson, 2003; Alwahassi et al., 2014; Bérnard-
Labière et al., 2015). It has been estimated that the risk of ADR
is 4 times higher in the elderly than the rest of the population
(Beijer and de Blaey, 2002). DDIs, ADRs, and ADEs are known
to weaken the quality of life and increase the risk for morbidity
andmortality (Onder et al., 2002; Hohl et al., 2013; Gutherie et al.,
2015). Understandably, they are also a common cause of geriatric
hospitalizations.
The aim of this study was to (1) determine the number
of patients admitted to Oulu University Hospital emergency
department due to ADEs, and (2) to observe if we could find leads
to the potential means of recognizing patients with medication-
related admission from larger patient populations.
MATERIALS AND METHODS
Study Design
This was a retrospective study in which data was collected from
the 2014 emergency department (ED) patient records from a
tertiary care teaching hospital, Oulu University Hospital, in
Oulu, Finland. In 2014, there were 11499 ED special healthcare
admissions to Oulu University Hospital by geriatric patients.
From these admissions, 290 (2.5%) cases were selected for this
study by a systematic random selection (Figure 1). All included
admissions were made by patients aged 65 or over and treated in
special healthcare unit. Patients admitted to ED nurse’s reception
or ED primary healthcare unit were not included in this study.
Medication record screening for potential ADEs related to
hospital admissions was performed by a multi-disciplinary team
including a pharmacist, a clinical pharmacologist, and a health
science researcher. Databases, such as the Swedish, Finnish
Interaction X-referencing (SFINX), Pharmacological Assessment
on-line (PHARAO), and the geriatric medicine database created
by Finnish Medicine Agency were used to detect DDIs, and
potential ADRs, and ADEs. Although the causality assessment
conducted by the research team was considered the final
assessment, the customized Naranjo scale was also applied as
control method (Table 1). The use of patient record data for
this study was granted by the Oulu University Hospital’s medical
director and approved by the Regional Ethics Committee of the
Northern Ostrobothnia Hospital District.
The World health Organization (WHO) defines ADRs as
“noxious or unintended response to drug occurring at doses
normally used in man for the prophylaxis, diagnosis or therapy
of disease, or for modification of physiological function” (World
Health Organization, 2002). ADE is defined as an untoward or
unintended event that occurs while patient is taking a drug,
but is not necessarily directly caused by the drug. According
to this definition ADEs can occur as untoward or unintended
injuries, symptoms, signs or abnormal laboratory values arising
from appropriate or inappropriate use of medication (Edwards
and Aronson, 2000; Hohl et al., 2013). ADEs therefore include
reactions directly linked to drug intake (ADR, DDI) and indirect
untoward events attributable to medication use (Stausberg,
2014). Medication-related hospitalization is defined as ED
admission caused by an ADE. Admissions for the treatment of
attempted suicide or suboptimal medication were not considered
medication-related. Polypharmacy was defined as simultaneous
use of multiple drugs (World Health Organization, 2004).
Although there is no distinct number of medications agreed
upon to define polypharmacy, it is commonly characterized as
concomitant use of 5 or more drugs (World Health Organization,
2004; Gutherie et al., 2015).
Data Collection
The 290 ED admission cases selected for this study were achieved
by assigning each 2014 special healthcare admission a number
(1–11,499) and including every fortieth case. The systematic
randomization method used was applied to obtain a sample that
had little or no bias due to seasonal and population variables.
Sample selection method allowed one patient to appear multiple
times in the sample due to separate admissions to the ED. If
information on medication regimen or reason for admission was
lacking, the case was excluded from the sample and replaced by
the next ED admission on the created admissions-list. On this
basis, 111 admissions were excluded from the sample. No other
exclusion criteria were used. All data was anonymized.
Included admissions were tested for bias toward the selected
variables (age, sex, specialty, month of ED admission). No bias
toward any of these variables were detected (min p= 0.630).
However, it was noted that a relatively larger amount of surgical
patients and a smaller amount of internal medicine patients were
excluded than expected. In addition, the amount of included
surgical patients was smaller and the amount of internal medicine
patients was higher than expected. This was not considered
to be caused by faulty sampling, but rather by expressing
differences in documenting medication information amongst
different specialties.
Electronic patient records for each included ED visit were
reviewed. Information on patients’ demographics (age, sex,
living arrangement), comorbidities, medication regimen, ADE,
drug interactions, and reason for admission was gathered.
When relevant, information was supplemented with the
patient’s laboratory results. Admissions were divided into groups
according to different sociodemographic variables for further
analysis (Table 2).
The causality of ADE and reason for admission was assessed
by the multi-disciplinary research team. In addition, causality
assessment was conducted with the customized Naranjo scale
as a control method. Because the research was conducted
retrospectively it was not possible for any single case to receive
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FIGURE 1 | Study design.
TABLE 1 | Assessment criteria used by the research team and the customized Naranjo scale.
Expert panel Customized Naranjo scale
Probable • Plausible relationship to drug intake Points 5–8
• Definite pharmacological or phenomenological explanation
• Definite laboratory results indicating ADR/drug interaction
• Drug recently added to medication regimen
Possible • Plausible relationship to drug intake Points 1–4
• Definite pharmacological or phenomenological explanation
Doubtful • No definite pharmacological or phenomenological explanation Points ≤ 0
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TABLE 2 | Sociodemographic details of the study sample (n = 290).
Parameter Medication related admission
Yes (n = 67) No (n = 223)
Gender [n (%)] Male 27 (18.9) 116 (81.1)
Female 40 (27.2) 107 (72.8)
Age [n (%)] 65–74 y 21 (19.3) 88 (80.7)
75–84 y 29 (21.8) 104 (78.2)
85–95 y 17 (35.4) 31 (64.6)
Comorbidities [n (%)] 0 2 (9.1) 20 (90.9)
1–4 31 (19.9) 125 (80.1)
5–8 28 (31.8) 60 (68.2)
≥9 6 (25.0) 18 (75.0)
Residence [n (%)] Community-dwelling 59 (22.4) 204 (77.6)
Institution 8 (29.6) 19 (70.4)
Number of regular medications [n (%)] 0 1 (6.7) 14 (93.3)
1–5 11 (11.6) 84 (88.4)
6–10 33 (28.9) 81 (71.1)
11–15 19 (36.5) 33 (63.5)
≥16 3 (21.4) 11 (78.6)
Number of medicines taken “when necessary” 0 11 (12.4) 78 (87.6)
1–3 33 (23.7) 106 (76.3)
4–6 19 (40.4) 28 (59.6)
≥7 4 (26.7) 11 (73.3)
Polypharmacy [n (%)]* Yes 58 (28.2) 148 (71.8)
No 9 (10.7) 75 (89.3)
Specialty [n (%)] Internal medicine 33 (21.0) 124 (79.0)
Surgery 21 (30.9) 47 (69.1)
Neurology 11 (18.6) 48 (81.4)
Other 2 (33.3) 4 (66.7)
Age [y: mean ± SD (range)] 79.2 ± 7.9 (65–94) 76.3 ±7.3 (65–95)
Comorbidities [mean ± SD (range)] 4.9 ± 2.5 (0–12) 3.9 ± 2.6 (0–12)
Number of regular medication [mean ± SD (range)] 9.1 ± 4.0 (0–22) 6.8 ± 4.5 (0–22)
Number of medication used “when needed” [mean ± SD (range)] 2.8 ± 2.2 (0–11) 2.0 ± 2.3 (0–15)
Information on patients’ demographics (age, sex, living arrangement), comorbidities, medication regimen, ADE, drug interactions, and reason for admission was gathered from electronic
patient records. Admissions were divided into groups according to different sociodemographic variables for further analysis.
*OR 3.3; 95% CI, 1.5–6.9; p = 0.001.
more than 7 points on the Naranjo assessment scale (e.g., it was
not possible to answer the questions “did the reaction appear
when placebo was given?” “did the reaction reappear when
drug was readministered,” and the answer to the question “are
there alternative causes that could on their own have caused
the reaction” was consistently “yes”). Accordingly, the Naranjo
scale could not be used in this study to indicate causality
as “definite.” Therefore, the results from both research team
assessment and the Naranjo assessment criteria were divided into
three categories; probable, possible and doubtful. Each of the
visits was categorized into one of these groups. The assessment
criteria of both research team and the customized Naranjo
assessment scale are presented in Table 1.
Statistics
Statistical analysis was carried out using SPSS Statistics 23.0
(SPSS Inc., Chicago, IL, USA). Descriptive statistics were used
to describe patient characteristics. Pearson’s chi-squared tests
(χ2) were used to test the relationship between discontinuous
variables. The differences between the sociodemographic data
and mean values were examined by t-tests or Analysis of variance
(ANOVA) with post-hoc Tuckey tests. Odds ratio (OR) was used
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to estimate the value of the association of certain variables and
hospitalization and it was presented with its 95% CI. p< 0.05 was
set as the level of statistical significance in the two sided approach.
RESULTS
The research data consisted of 290 ED admissions made by
287 patients. Of these admissions, the majority was made to
the specialties of internal medicine, neurology, and surgery.
The rest of the specialties (dental surgery, ear, nose and
throat diseases, ophthalmology, and gynecological diseases) were
grouped as “others.” Most admissions were made by community-
dwelling patients and only a minority of the patients was from
institutionalized care.
The age of the patients varied between 65 and 95 years
and the average age was 77 years. For further analysis, patients
were divided into three age groups, 65–74, 75–84, and 85–95
years (Table 2). In comparison, the youngest age group had
significantly less comorbidities than the older age groups (mean
value 3.5 vs. 4.5 and 4.8, p = 0.004, respectively). A significant
variation between age groups was also detected in the number
of regular medications and medicines taken “when necessary.”
The average number of regular medicines increased with age; in
the youngest age group the number of regular medicines was
6.6, in the middle age group 7.5, and in the oldest age group
8.9 (p= 0.012),whereas the number of medicines used “when
needed” was 2.0 for the two younger age groups and 3.1 for the
oldest (p = 0.04). The majority (n = 206, 71%) of the patients
were affected by polypharmacy. Age was found to increase the
likelihood for polypharmacy (p < 0.001). Residence, however,
did not appear to affect the relative risk for polypharmacy in our
study small sample (p= 0.268).
Out of 290 admissions, 67 (23.1%) were found “probably” or
“possibly” medication-related (n = 38 and n = 29, respectively)
(Table 2). Age, sex, residence, or specialty did not affect the
appearance of medication-related admissions (min p = 0.077).
Polypharmacy, on the other hand, was found to increase the
likelihood for medication-related hospital admission (p= 0.01).
Multiple ADEs presented in the medication-related
admissions (Table 3). Although the distribution of the ADEs was
wide “vertigo, falling, and fractures” was identified as the most
common group of ADEs in the study sample. The group “others”
included single incidences of ADEs such as impaired mobility,
sweating, nausea, leukopenia, unconsciousness, swelling, and
wounds in skin and oral mucosa. Only 27 (40.3%) ADEs of the
found 67 ADEs were detected at the time of admission to the ED.
Altogether 121 drugs from 9 different ATC groups
(Anatomical Therapeutic Chemical Classification System)
were involved in the ADEs (Figure 2). The majority (64, 52.9%)
of the drugs were N class medication (nervous system) (Table 4).
Medicines from L (antineoplastic and immunomodulating
agents) and C (Cardiovascular disease) classes were also
frequently associated with found ADEs. Together these three
TABLE 3 | Detected ADEs in the study sample of 290 ED admissions and medications related to them (n = 67).
ADE description Number of events, n = 67 (%) Causative drug (times involved in ADE)
Falling, vertigo, fractures 13 (19.4%) Oxycodone(3), diazepam(3), isosorbide mononitrate(2), memantine(3),
levodopa(3), risperidone(2), hydroxyzine(2), isosorbide dinitrate(1), lithium(1),
haloperidol(1), temazepam(1), mirtazapine(2), topiramate(1), amitriptyline(1),
tramadol(1), tiotropium(1), rivastigmin(1), nifedipine(1), codein(1), glyseryl
trinitrate(1), tizanidine(1)
Bleeding 8 (12.0%) Warfarin(5), prednisolone(1), acetylsalicylic acid(1), clopidogrel(1),
enoxaparin(1), venlafaxine(1)
ADR or infection after cytostatics
treatment
8 (12.0%) Docetaxel(2), fluorouracil(1), azacitidine(1), panitumumab(1), tamoxifen(1),
rituximab(1), cyclophosphamide(1), epirubicin(1), doxorubicin(1),
vincristine(1), methotrexate(1), temozolomide(1)
Disorientation, delirium, memory loss 6 (8,9%) Fentanyl(1), Buprenorphine(1), clonazepam(1), carbamazepine(1),
zopiclone(1), amitriptyline(1), diazepam(1), chlordiazepoxide(1), tramadol(1),
oxycodone(1)
Constipation, occlusion 6 (8.9%) Buprenorphine(2), risperidone(2), ispagula extract(1), loperamide(1),
amitriptyline(1), chlordiazepoxide(1), codein(1), haloperidol(1), quetiapine(1),
duloxetine(1), oxycodone(1), memantine(1)
Decrease in general condition 6 (8.9%) Buprenorphine(1), donepezil(1), digoxin(1), oxycodone(1), pregabalin(1),
escitalopram(1), quetiapine(1), prednisolone(1), carbamazepine(1),
duloxetine (1), isosorbide mononitrate(1), ramipril(1)
Infection after immunosuppressive
treatment
5 (7.5%) Methylprednisolone(1), Prednisolone(3), hydrocortisone(1)
Arrhythmias 4 (6.0%) Donepezil(1), solifenazin(1), digoxin(1), verapamil(1), bisoprolol(1),
furosemide(1)
Convulsion 3 (4.5%) Citalopram(1), quetiapine(1), duloxetine(1), fesoterodine(1), tiotropium(1),
teophyllin(1), risperidone(1), mirtazapine(1)
Other 8 (11.9%) Calcium(1), iron(1), scopolamine(1), enalapril(1), clozapine(1), levodopa(1),
lerchanidipin(1), azathioprine(1), furosemide(1), metformin(1)
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FIGURE 2 | Distribution of medicines involved in ADEs by ATC codes (n = 121) according to research team and customized Naranjo scale.
groups covered 76% of all medicines causing ADEs in the study
sample. The majority of the ADEs resulted from additive effect
of more than 1 medicine. Furthermore, medicines from the
different ATC groups could be involved in the same ADE.
All the included study admissions were assessed by the
customized Naranjo scale alongside the research team’s causality
assessment. The purpose of this was to determine whether there
was any differences in detection of ADEs between the two
methods. To make the comparison easier, the results from both
assessment methods were categorized into three similar groups
(probable, possible, and doubtful).
In total, 223 and 226 admissions were categorized “doubtful”
by research team and customized Naranjo scale, respectfully
(Figure 3). 217 of these admissions were categorized “doubtful”
by both of the assessment methods. In the two other groups
the distribution was larger. The customized Naranjo scale placed
the majority of the remaining admissions as “possible,” whereas
the research team categorized admissions more evenly between
“probable” and “possible.” Only six admissions were categorized
by both assessment methods as “probable.”
DISCUSSION
To our knowledge, there are no studies published on the
prevalence of geriatric hospitalizations due to ADEs in
Finland. This research therefore provides valuable information
on national challenges faced when medicating the elderly.
International studies have shown that ADEs cause approximately
5–50% of all geriatric hospital admissions with large deviations
mainly resulting from definition differences (Budnitz et al., 2007;
Pascale et al., 2009; Alwahassi et al., 2014; Davies and O’Mahony,
TABLE 4 | The distribution of ATC-code N class medicines involved in
found ADEs (n = 64).
ATC code No. of medications
N nervous system n = 121 (%)
N02A Opioid drugs 15 (12.4%)
N03A Antiepileptic drugs 5 (4.1%)
N04 Antiparkinsonian drugs 4 (3.3%)
N05A Antipsychotic drugs 12 (9.9%)
N05B Anxiolytic drugs 7 (5.8%)
N05C Hypnosis and sedative drugs 2 (1.7%)
N06A Antidepressant drugs 11 (9.1%)
N06CA Antidepressants in combination with
psycholeptics
1 (0.8%)
N06D Dementia drugs 7 (5.8%)
2015). In this study sample, ADEs were discovered to cause
23.1% of geriatric ED hospitalizations and thereby placing the
prevalence significantly higher than the 10% median of ADR-
related hospitalizations in recent review (Alwahassi et al., 2014).
Out of the 290 patients included in this study, 157 were
treated in the specialty of internal medicine whereas the number
of included surgical patients was 68. The expected number of
included patients in internal medicine and surgery were 122
and 105, respectively. In addition, the number of excluded
patients in internal medicine and surgery were 18 and 75 and
the expected number of excluded patients 47 and 40, respectively.
Accordingly, fewer patients were included and far less patients
excluded from surgery than expected. As all the exclusions made
were due to lacking information on medication regimen, it
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FIGURE 3 | Causality assessment; comparison the causality assessment of research team and the customized Naranjo scale (n = 290).
was concluded that medication was not reconciled in a large
fraction of surgical patients in ED during admission posing
a significant threat to overall patient safety during treatment.
Consequently, medication-related admissions appeared more
frequently in surgical patients than in internal or neurological
patients. The reasons for the inadequate documentation of
medication regimen could not be established but the findings
emphasize the need for consistent medication reconciliation in
all specialties.
There was no statistically significant difference in the
occurrence of medication-related hospitalization between age
groups, sex, specialties, or residence in our small study sample.
Polypharmacy, on the other hand, was found to increase the risk
of medication-related admissions. The most common group of
ADEs (20.9%) was “vertigo, falling, and fractures.” However, the
difference between this and the other ADE groups was small
indicating fairly heterogeneous expression of ADEs. The overall
results on factors related to ADEs suggest that screening for
patients with specific demographics or symptoms would not
result in improved detection of ADEs in the patient population.
Furthermore, recognizing patients with ADEs on larger scale
would require more effective ways of data-mining in addition to
more accurately focused resources.
In this study, we found medicines from the ATC N class
(nervous system) to cover most of the medicines (52.9%)
involved in ADEs. Furthermore, the N class medicines took part
in all ADE groups except “infection after immunosuppression”
and “ADR or infection caused by cytostatics.” Previously,
drugs from this category have been associated with falling,
anticholinergic symptoms, delirium, cerebrovascular events,
parkinsonism, and oversedation of geriatric patients (Ballard
et al., 2006; Woolcott et al., 2009; Clegg and Young, 2011;
Gillespie et al., 2012; Hovstadius et al., 2014; Palmer et al.,
2015; Salahudeen et al., 2015). In our study, the most frequent
subgroups leading to ADEs were opioids, antipsychotics and
antidepressants. Adverse outcomes were especially associated
with simultaneous use of several drugs from these groups. In this
small study, however, we could not say whether the ADE was
preventable or not.
When compared with each other, the assessment by research
team and the customized Naranjo scale assessed a near equal
amount of admissions “doubtful.” Nevertheless, much variation
was discovered between the groups “probable” and “possible.”
The customized Naranjo scale was inclined to assign more
admissions to “possible” whereas, research team categorized
more admissions as “probable.” Most of the variation can be
explained by huge contrast in method flexibleness. The research
team could regard a variety of affecting variables in the decision
making whereas the Naranjo scale is based on fixed questions.
The fixed nature of structured assessment methods has been
considered one of its best assets as the result shouldn’t vary
between different assessors. However, structured methods are
often insufficient when assessing cases in complex context, e.g.,
polypharmacy or multimorbidity. Thus, in a clinical setting the
ability to adapt has greater significance in distinguishing the
“probable” from the “possible.”
There are some limitations in this study. The take of 290
patients is small as well as the number of patients hospitalized
due to ADEs. This must be considered when interpreting the
results. Relatively large number of surgical patients was excluded
as a result of missing medication information. Due to the
retrospective nature of the study it was not possible to gather data
concerning some variables, e.g., frailty, that could have affected
the outcome. This study, however, provides valuable information
on admissions caused by ADE in the aged population.
Most of the current efforts to detect ADEs are centered on
voluntary reporting systems, retrospective manual tracking of
errors, and different chart audits. Pharmacovigilance actions
and risk management—although prospectively included in
modern drug development—are however methodologically
based on follow-up and focused on signal detection, rather
than prevention and clinical management of ADEs. In the end,
with such approaches, only 5–10% of ADEs are ever reported
and, of those, up to 95% actually do not cause any harm to
the patient, clearly indicating that these traditional methods
are insensitive, ineffective and expensive (Naessens et al., 2009;
Classen et al., 2011; Kennerly et al., 2014). The majority of ADEs
could, however, be predicted and avoided beforehand. Thus, it is
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evident that there is a great need for more effective approaches to
identify and prevent ADEs in order to reduce harm.
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